

Dear Colleagues,

I invite you to read the third number of the *Journal of Hearing Science* for 2022. The issue consists of five original research papers and one case study. The studies cover some interesting topics: the performance of hearing aids in noise, cases of Type 1 neurofibromatosis, reporting standards for clinical trials of tinnitus, unusual factors that might increase hearing loss, and, finally, a study of biochemical markers in deaf children which may be useful for gauging neuroplasticity following cochlear implantation – and hence the likely success of the operation.

All these topics are emerging, but the study on reporting the outcomes of clinical trials focused on tinnitus strikes me as being especially important. Tinnitus is an elusive phenomenon, both scientifically and more importantly clinically – how can we accurately diagnose and treat the condition? Years of research pass and we still seem far from finding a solution. According to the paper in this issue, solving the problem would be helped if research on it is conducted according to the highest possible standards, which presently seem to be lacking. The paper emphasises that clinical trials should be documented in such a way that full knowledge of what was done is made clear, and that reproducibility is easy.

The issue concludes with an interesting case study of the quality of life of two patients who had neurodegenerative disease and dysarthria.



With kind regards and greetings,

*Prof. Henryk Skarzynski, M.D., Ph.D., Dr. h.c. multi*